Improvement of headache symptoms and reduction in headache medication usage in patients treated with botulinum toxin type A

References

• Cheung RTF. Prevalence of migraine, tension-type headache, and other headaches in Hong Kong. Headache 2000; 40: 473–479.
   PubMed Web of Science ®Google Scholar
• Deleu D, Khan MA, Al Shehab TAH. Prevalence and clinical characteristics of headache in a rural community in Oman. Headache 2002; 42: 963–973.
   PubMedGoogle Scholar
• Göbel H, Petersen-Braun M, Soyka D. The epidemiology of headache in Germany: a nationwide survey of a representative sample on the basis of the headache classification of the International Headache Society. Cephalalgia 1994; 14: 97–106.
   PubMed Web of Science ®Google Scholar
• Rasmussen BK, Jensen R, Schroll M et al. Epidemiology of headache in a general population – a prevalence study. Journal of Clinical Epidemiology 1991; 44: 1147–1157.
   PubMed Web of Science ®Google Scholar
• Castillo J, Muñoz P, Guitera V, Pascual J. Epidemiology of chronic daily headache in the general population. Headache 1999; 39: 190–196.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Stewart WF, Diamond S et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41: 646–657.
   Google Scholar
• Lipton RB, Scher AI, Kolodner K et al. Migraine in the United States: epidemiology and patterns of health care use. Neurology 2002; 58: 885–894.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Rapoport AM, Lipton RB et al. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache 2003; 43: 336–342.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Hamelsky SW, Kolodner KB et al. Migraine, quality of life, and depression: a population-based case-control study. Neurology 2000; 55: 629–635.
   PubMed Web of Science ®Google Scholar
• Guitera V, Muñoz P, Castillo J et al. Quality of life in chronic daily headache: a study in a general population. Neurology 2002; 58: 1062–1065.
   PubMed Web of Science ®Google Scholar
• Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics 1998; 13: 667–676.
   PubMed Web of Science ®Google Scholar
• Clouse JC, Osterhaus JT. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Annals of Pharmacotherapy 1994; 28: 659–664.
   PubMed Web of Science ®Google Scholar
• Hu XH, Markson LE, Lipton RB et al. Burden of migraine in the United States: disability and economic costs. Archives of Internal Medicine 1999; 159: 813–818.
   PubMed Web of Science ®Google Scholar
• Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics 1992; 2: 67–76.
   PubMedGoogle Scholar
• Redillas C, Solomon S. Prophylactic pharmacological treatment of chronic daily headache. Headache 2000; 40: 83–102.
   PubMed Web of Science ®Google Scholar
• Adelman JU, Von Seggern R. Cost considerations in headache treatment. Part 1: prophylactic migraine treatment. Headache 1995; 35: 479–487.
   PubMed Web of Science ®Google Scholar
• Archibald N, Lipscomb J, McCrory DC. Resource utilization and costs of care for treatment of chronic headache. Technical review 2.1. February 1999. Prepared for the Agency for Health Care Policy and Research under Contract No. 290-94-2025. Available at: http://www.clinpol.mc.duke.edu. Accessed June 6, 2003.
   Google Scholar
• Clarke CE, MacMillan L, Sondhi S, Wells NEJ. Economic and social impact of migraine. QJM: Monthly Journal of the Association of Physicians 1996; 89: 77–84.
   PubMed Web of Science ®Google Scholar
• Rasmussen BK, Jensen R, Olesen J. Impact of headache on sickness absence and utilisation of medical services: a Danish population study. Journal of Epidemiology and Community Health 1992; 46: 443–446.
   PubMed Web of Science ®Google Scholar
• Edmeads J, Findlay H, Tugwell P et al. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Canadian Journal of Neurological Sciences 1993; 20: 131–137.
   PubMed Web of Science ®Google Scholar
• Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache 2003; 43: 36–43.
   PubMed Web of Science ®Google Scholar
• Naumann M, Yakovleff A, Durif F, for the BOTOX® Cervical Dystonia Prospective Study Group. A randomized, double- masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. Journal of Neurology 2002; 249: 57–63.
   Google Scholar
• Jankovic J, Schwartz KS. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology 1993; 43: 834–836.
   Google Scholar
• Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. New England Journal of Medicine 1991; 324: 1186–1194.
   PubMed Web of Science ®Google Scholar
• Brashear A, Gordon MF, Elovic E et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. New England Journal of Medicine 2002; 347: 395–400.
   PubMed Web of Science ®Google Scholar
• Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003; 43: S9–S15.
   PubMed Web of Science ®Google Scholar
• Morris JL, Jobling P, Gibbins IL. Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. American Journal of Physiology/Heart and Circulatory Physiology 2001; 281: H2124–H2132.
   Web of Science ®Google Scholar
• Ishikawa H, Mitsui Y, Yoshitomi T et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Japanese Journal of Ophthalmology 2000; 44: 106–109.
   PubMed Web of Science ®Google Scholar
• Silberstein S, Mathew N, Saper J et al, for the BOTOX® Migraine Clinical Research
   Google Scholar
• Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache 2003; 43: 171–178.
   PubMed Web of Science ®Google Scholar
• Adelman JU, Adelman LC, Von Seggern R. Cost-effectiveness of antiepileptic drugs in migraine prophylaxis. Headache 2002; 42: 978–983.
   PubMed Web of Science ®Google Scholar
• Adelman JU, Brod A, Von Seggern RL et al. Migraine preventive medications: a reappraisal. Cephalalgia 1998; 18: 605–611.
   PubMed Web of Science ®Google Scholar
• Blumenfeld A. Decrease in headache medication use and cost after botulinum Group. Botulinum toxin type A as a toxin type A (Botox ) treatment in a high migraine preventive treatment. Headache 2000; 40: 445–450.
   PubMedGoogle Scholar
• Smuts JA, Baker MK, Smuts HM et al. Prophylactic treatment of chronic tension- type headache using botulinum toxin type A. European Journal of Neurology triptan use population. Presented at the 44th Annual Scientific Meeting, American Headache Society, June 21- 23, 2002, Seattle, Washington. Headache 2002; 42: 389–463.
   Google Scholar
• Barrientos N, Chana P. Efficacy and safety 1999; 6: S99–S102. of botulinum toxin type A (Botox ) in the
   Google Scholar
• Blumenfeld AM, Binder W, Silberstein SD et al. Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache 2003; 43: 884–891.
   PubMed Web of Science ®Google Scholar
• Maizels M. Health resource utilization of the emergency department headache “repeater.” Headache 2002; 42: 747–753. prophylactic treatment of migraine. Journal of Headache and Pain 2003; 4: 146–151.
   PubMed Web of Science ®Google Scholar
• Mathew NT, Kailasam J, Meadors L. “Disease modification” in chronic migraine with botulinum toxin type A: long-term experience [abstract]. Headache 2002; 42: 389–463.
   Google Scholar